uso 22326
CAMBRIA-2: A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor o Tamoxifen) bilang Adjuvant Treatment para sa mga Pasyente Sa ER+/HER2- Maagang Kanser sa Dibdib at isang Intermediate-high o Mataas na panganib ng Pag-ulit na Nakumpleto ang Definitive Locoregional na Paggamot at Walang Katibayan ng Sakit (D8535C00001)
Mga Uri ng Sakit: Pananaliksik sa Kanser sa Suso
Mga Kinakailangan sa Kwalipikasyon:
-Women and Men, >18 years at the time of screening (or per national guidelines) -Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with high or intermediate risk of recurrence, based on clinical-pathological risk features, as defined in the protocol. -Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy --Completed at least 2 years but no more than 5 years (+3 months) of adjuvant ET (+/- CDK4/6 inhibitor) -Eastern Cooperative Oncology Group (ECOG) performance status of < 1 -Adequate organ and marrow function
Available sa:
- Chesapeake
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Norfolk (Brock Cancer Center)
- Virginia Beach ( Princess Anne )
- Williamsburg